SecBot SecBot
8-K ·Filed Aug 5, 2026

CMPS

COMPASS Pathways plc
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago SEC0001816590-26-000059
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The GAAP EPS miss is noise due to warrant accounting; the core catalyst is the NDA submission and potential approval of COMP360. Monitor for Part B data from COMP006 in early Q3 and final NDA submission in Q4, which are the key value drivers. The strong cash position removes near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.58
T+0 close · Aug 5, 2026 · via day close
Latest settled
−11.05%
T+60 · $12.08
Vs SPY
−11.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $13.58entry
  2. T+1 · 3mo ago −0.22%α −0.06% · $13.55
  3. T+5 · 3mo ago +4.71%α +4.36% · $14.22
  4. T+20 · 3mo ago −2.58%α −1.98% · $13.23
  5. T+60 · 19d ago −11.05%α −11.24% · $12.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Compass Pathways reported Q2 2026 results with a net loss of $1.88 per share, a wider loss vs $0.41 in Q2 2025, driven by non-cash warrant liability fair value adjustments. The core operational story remains on track: NDA rolling submission for COMP360 in TRD is underway with final submission expected in Q4, and commercial launch is targeted for H1 2027. The company holds $433M in cash, sufficient into 2028, but the GAAP loss miss vs consensus and the GAAP net loss widening are the headline financials for this pre-revenue biotech.

Key Financial Metrics

EPS
−$1.88
est −$0.34 · -452.9%
Rating
miss

Key Facts

  • Net loss of $253.8M ($1.88/share) for Q2 2026 vs $38.4M ($0.41/share) in Q2 2025, primarily due to a $205.6M non-cash loss from warrant liability fair value adjustments.
  • Cash and cash equivalents of $433.3M as of June 30, 2026, compared to $149.6M at December 31, 2025.
  • Rolling NDA submission for COMP360 in TRD is underway; final submission on track for Q4 2026.
  • Commercial launch expected in first half of 2027, subject to FDA approval and DEA rescheduling.
  • Operating expenses (R&D + G&A) were $52.4M in Q2 2026, up from $42.9M in Q2 2025, driven by increased commercial preparedness costs.
  • EPS of -$1.88 missed the consensus estimate of -$0.34 by a wide margin, though this is a pre-revenue biotech where GAAP EPS is heavily influenced by non-cash warrant adjustments.

Financial Impact

GAAP net loss per share of -$1.88 vs consensus -$0.34, a significant miss driven by non-cash warrant revaluation. Cash burn from operations (not explicitly stated but implied by operating loss of $52.4M) is the core financial metric for this pre-revenue company.

net lossepscash

Risk Factors

  • FDA approval of COMP360 is not guaranteed; the NDA review could result in a Complete Response Letter (CRL).
  • DEA rescheduling of psilocybin is required before commercialization and faces political and regulatory uncertainty.
  • Commercial adoption of a novel psychedelic treatment paradigm is unproven and may be slower than anticipated.
  • The company is pre-revenue and will continue to generate operating losses until a potential product launch.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001816590-26-000059
Document: cmps-20260805.htm0001816590-26-000059
Document: 0001816590-26-000059-index-headers.html0001816590-26-000059
Document: 0001816590-26-000059-index.html0001816590-26-000059
Document: 0001816590-26-000059.txt0001816590-26-000059
8-K Data (Synthetic)0001816590-26-000059

Track record

6 reports on CMPS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $8.59 to $9.25 Now $8.27 −3.73% ▲ +7.68% +8.27% vs SPY
  2. Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $12.28 to $8.60 Now $8.27 −32.65% ▼ −29.97% −29.26% vs SPY
  3. Aug 10, 202614w ago 144 Neutral 3/10 Entry $13.18 to $13.72 Now $8.27 −37.25% ▲ +4.10% +4.14% vs SPY
  4. Aug 5, 202614w ago 8-K Neutral 5/10 Viewing Entry $13.58 to $14.22 Now $8.27 −39.10% ▲ +4.71% +4.36% vs SPY
  5. Jul 7, 202618w ago 8-K Neutral 3/10 Entry $12.99 to $13.39 Now $8.27 −36.34% ▲ +3.08% +2.53% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $11.41 to $11.94 Now $8.27 −27.52% ▲ +4.64% +4.21% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026